LENZ insider buying and SEC filings, explained
LENZ Therapeutics, Inc. · CIK 1815776
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Graphite Bio, Inc.
Insider activity in the last 12 months
Bought
$655K
Insiders who bought
4
Sold (not marked 10b5-1)
$9.1M
Planned sales (10b5-1)
$261K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 29, 2026 | Sale | Peter Kolchinsky (10% owner) sold 2,718,684 shares indirectly at about $3.36 ($9.1M). Indirect holdings down 98% to 57,559 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed Nov 2, 2026, 5:44 PM ET |
| Mar 27, 2026 | Purchase (code P) | Jeffrey P. George (Director) bought 5,592 shares at about $8.92 ($50K), reported as a purchase (code P). New position of 5,592 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 30, 2026 |
| Mar 27, 2026 | Purchase (code P) | Evert B. Schimmelpennink (CEO and Director) bought 28,089 shares at about $8.95 ($251K), reported as a purchase (code P). Holdings up 57% to 77,289 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 30, 2026 |
| Mar 27, 2026 | Purchase (code P) | Daniel R. Chevallard (CFO) bought 7,500 shares at $8.57 ($64K), reported as a purchase (code P). Holdings up 139% to 12,886 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 30, 2026 |
| Nov 17, 2025 | Planned (10b5-1) | Shawn Olsson (Chief Commercial Officer) sold 10,000 shares at about $26.10 ($261K), marked as a 10b5-1 plan trade. Holdings down 68% to 4,733 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 7, 2025 | Purchase (code P) | James W. Mccollum (Director) bought 10,500 shares at about $22.79 ($239K), reported as a purchase (code P). New position of 10,500 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 10, 2025 |
| Nov 7, 2025 | Purchase (code P) | Daniel R. Chevallard (CFO) bought 2,198 shares at about $22.76 ($50K), reported as a purchase (code P). Holdings up 69% to 5,386 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 7, 2025 |
13 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
3 insiders bought in 30 days
$366K in purchases since Mar 27, 2026 · Purchases traded Mar 27, 2026 to Mar 27, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Daniel R. Chevallard (CFO) | $64K | Mar 27, 2026 | SEC filing |
| Evert B. Schimmelpennink (CEO) | $251K | Mar 27, 2026 | SEC filing |
| Jeffrey P. George (Director) | $50K | Mar 27, 2026 | SEC filing |
2 insiders bought in 30 days
$289K in purchases since Nov 7, 2025 · Purchases traded Nov 7, 2025 to Nov 7, 2025 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Daniel R. Chevallard (CFO) | $50K | Nov 7, 2025 | SEC filing |
| James W. Mccollum (Director) | $239K | Nov 7, 2025 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
| Tag | Items | Filed | Source |
|---|---|---|---|
| CEO and CFO departure Detected from the filing text | 8-K Item 5.02 | Oct 28, 2026, 4:34 PM ET | SEC filing |
| Restructuring | 8-K Item 2.05 | Oct 28, 2026, 4:34 PM ET | SEC filing |
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Oct 28, 2026, 4:34 PM ET 8-K | Earnings released (Item 2.02) Restructuring or exit costs (Item 2.05) Executive or director change (Item 5.02) | CEO and CFO departure Detected from the filing text Restructuring | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow LENZ in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.